CA1084791A - Anneau vaginal - Google Patents

Anneau vaginal

Info

Publication number: CA1084791A
Authority: CA; Canada
Prior art keywords: ring; active substance; ltv; polysiloxane; support ring
Prior art date: 1974-10-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA237,945A

Other languages

English (en)

Inventor

Gisela Schopflin

Gerhard Laudahn

Barbara Muhe

Heidemarie Hartmann

Fred Windt

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Schering AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1974-10-18

Filing date

1975-10-20

Publication date

1980-09-02

1974-10-18 Priority claimed from DE2450103A external-priority patent/DE2450103C3/de

1975-08-21 Priority claimed from DE19752537585 external-priority patent/DE2537585A1/de

1975-10-20 Application filed by Schering AG filed Critical Schering AG

1980-09-02 Application granted granted Critical

1980-09-02 Publication of CA1084791A publication Critical patent/CA1084791A/fr

Status Expired legal-status Critical Current

Links

239000006213 vaginal ring Substances 0.000 title claims abstract description 65
229940044953 vaginal ring Drugs 0.000 title claims abstract description 45
239000013543 active substance Substances 0.000 claims abstract description 102
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 47
229920001296 polysiloxane Polymers 0.000 claims abstract description 47
229920002379 silicone rubber Polymers 0.000 claims abstract description 38
229910052697 platinum Inorganic materials 0.000 claims abstract description 21
239000004945 silicone rubber Substances 0.000 claims abstract description 12
150000003058 platinum compounds Chemical class 0.000 claims abstract description 7
125000000217 alkyl group Chemical group 0.000 claims abstract description 4
125000003118 aryl group Chemical group 0.000 claims abstract description 4
230000003197 catalytic effect Effects 0.000 claims abstract description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
229960004400 levonorgestrel Drugs 0.000 claims description 30
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical group O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 28
229920001971 elastomer Polymers 0.000 claims description 22
239000000806 elastomer Substances 0.000 claims description 21
239000000126 substance Substances 0.000 claims description 21
150000001875 compounds Chemical class 0.000 claims description 14
239000000463 material Substances 0.000 claims description 12
229920003023 plastic Polymers 0.000 claims description 9
239000004033 plastic Substances 0.000 claims description 9
239000003270 steroid hormone Substances 0.000 claims description 4
230000002254 contraceptive effect Effects 0.000 claims description 3
230000003152 gestagenic effect Effects 0.000 claims description 3
239000011148 porous material Substances 0.000 claims description 3
239000003433 contraceptive agent Substances 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000000962 organic group Chemical group 0.000 claims description 2
230000001076 estrogenic effect Effects 0.000 claims 2
239000000203 mixture Substances 0.000 description 89
239000000306 component Substances 0.000 description 83
238000000465 moulding Methods 0.000 description 64
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
239000004205 dimethyl polysiloxane Substances 0.000 description 27
235000013870 dimethyl polysiloxane Nutrition 0.000 description 27
238000004073 vulcanization Methods 0.000 description 27
239000000725 suspension Substances 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 20
239000000377 silicon dioxide Substances 0.000 description 18
235000012239 silicon dioxide Nutrition 0.000 description 18
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 16
229960002568 ethinylestradiol Drugs 0.000 description 16
-1 for example Substances 0.000 description 13
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 10
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 9
239000000243 solution Substances 0.000 description 9
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 9
239000003054 catalyst Substances 0.000 description 8
229920001577 copolymer Polymers 0.000 description 8
239000003814 drug Substances 0.000 description 8
238000010438 heat treatment Methods 0.000 description 8
238000000034 method Methods 0.000 description 8
229920000260 silastic Polymers 0.000 description 8
238000010276 construction Methods 0.000 description 7
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
229930182833 estradiol Natural products 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
101000623895 Bos taurus Mucin-15 Proteins 0.000 description 5
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000000262 estrogen Substances 0.000 description 5
239000008240 homogeneous mixture Substances 0.000 description 5
238000001746 injection moulding Methods 0.000 description 5
IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 5
229960001390 mestranol Drugs 0.000 description 5
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
229960000282 metronidazole Drugs 0.000 description 4
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 4
230000016087 ovulation Effects 0.000 description 4
239000000583 progesterone congener Substances 0.000 description 4
229920002631 room-temperature vulcanizate silicone Polymers 0.000 description 4
DNXHEGUUPJUMQT-UHFFFAOYSA-N 3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
230000031018 biological processes and functions Effects 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000000470 constituent Substances 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
229960000978 cyproterone acetate Drugs 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
229960000988 nystatin Drugs 0.000 description 3
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 3
QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
208000005448 Trichomonas Infections Diseases 0.000 description 2
206010044620 Trichomoniasis Diseases 0.000 description 2
229940045985 antineoplastic platinum compound Drugs 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000005266 casting Methods 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000010949 copper Substances 0.000 description 2
229960003843 cyproterone Drugs 0.000 description 2
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 2
JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 2
229960004913 dydrogesterone Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
229960003399 estrone Drugs 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
229940053934 norethindrone Drugs 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
239000005060 rubber Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
206010063659 Aversion Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000905957 Channa melasoma Species 0.000 description 1
JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
208000012287 Prolapse Diseases 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
229920004482 WACKER® Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940054053 antipsychotics butyrophenone derivative Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
IVFILROKUQKCPB-UHFFFAOYSA-N carbonyl dichloride;platinum Chemical compound [Pt].ClC(Cl)=O IVFILROKUQKCPB-UHFFFAOYSA-N 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical group S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
125000000068 chlorophenyl group Chemical group 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
229940099364 dichlorofluoromethane Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000001408 fungistatic effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
229960002899 hydroxyprogesterone Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960004719 nandrolone Drugs 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229920003052 natural elastomer Polymers 0.000 description 1
229920001194 natural rubber Polymers 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
229910000510 noble metal Inorganic materials 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003961 organosilicon compounds Chemical class 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
150000003057 platinum Chemical class 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
229910000077 silane Inorganic materials 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
229920001169 thermoplastic Polymers 0.000 description 1
239000004416 thermosoftening plastic Substances 0.000 description 1
150000003606 tin compounds Chemical class 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
125000005023 xylyl group Chemical group 0.000 description 1

Landscapes

Materials For Medical Uses (AREA)
Medicinal Preparation (AREA)
Compositions Of Macromolecular Compounds (AREA)

CA237,945A 1974-10-18 1975-10-20 Anneau vaginal Expired CA1084791A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DEP2450103.7		1974-10-18
DE2450103A DE2450103C3 (de)	1973-10-19	1974-10-18	Vorrichtung zur Behandlung einer Flüssigkeit, um eine dispergierte flüssige Phase aus einer kontinuierlichen flüssigen Phase zu entfernen
DE19752537585 DE2537585A1 (de)	1975-08-21	1975-08-21	Vaginalring ii
DEP2537585.3		1975-08-21

Publications (1)

Publication Number	Publication Date
CA1084791A true CA1084791A (fr)	1980-09-02

Family

ID=25767851

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA237,945A Expired CA1084791A (fr)	1974-10-18	1975-10-20	Anneau vaginal

Country Status (1)

Country	Link
CA (1)	CA1084791A (fr)

1975
- 1975-10-20 CA CA237,945A patent/CA1084791A/fr not_active Expired

Legal Events

Date	Code	Title	Description
1997-09-02	MKEX	Expiry

Publication	Publication Date	Title
US4012496A (en)	1977-03-15	Vaginal ring
US4155991A (en)	1979-05-22	Vaginal ring
US4292965A (en)	1981-10-06	Intravaginal ring
CA1049408A (fr)	1979-02-27	Preparation pharmaceutique contenant un elastomere du silicone
JP5017109B2 (ja)	2012-09-05	プロゲステロン受容体モジュレーターを含有する徐放性組成物
JP3970936B2 (ja)	2007-09-05	挿入自在の薬剤含有コアを有する膣内リング
US5035891A (en)	1991-07-30	Controlled release subcutaneous implant
EP0887074B1 (fr)	2003-10-22	Dispositif d'administration intravaginale de médicaments
US3545439A (en)	1970-12-08	Medicated devices and methods
US5733565A (en)	1998-03-31	Male contraceptive implant
JP2001524124A (ja)	2001-11-27	テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具
JPH08506318A (ja)	1996-07-09	ノメゲストロール誘導体に基づく皮下埋め込み物
JP2671953B2 (ja)	1997-11-05	膣挿入デバイス
US20190008763A1 (en)	2019-01-10	Copper intrauterine device
Sam	1992	Controlled release contraceptive devices: a status report
IE44736B1 (en)	1982-03-10	Vaginal ring
CA1084791A (fr)	1980-09-02	Anneau vaginal
EP1494646B2 (fr)	2017-10-04	Dispositifs d'apport par voie vaginale d'un medicament present dans une matrice
WO1992018101A1 (fr)	1992-10-29	Dispositif d'administration vaginale de substances medicamenteuses
US20200179274A1 (en)	2020-06-11	Drug delivery system for ultra-low dose estrogen combinations and methods and uses thereof
DE2450107A1 (de)	1976-04-29	Vaginalring
Nash et al.	1981	Patent: Intravaginal ring
DE2537585A1 (de)	1977-03-03	Vaginalring ii
Moo-Young et al.	1998	Patent: Male contraceptive implant
Ayeni	1990	A study of percutaneous drug delivery devices for the administration of progestins